Quick Answer
MRD is changing how blood cancers are monitored. Here is what the test means and how it is used.
Medically reviewed by Dr. Sachita Baniya • NMC 20158 • Kathmandu Neurology Clinic & Cognitive Center
When a bone marrow report says "no blasts seen," it means the microscope could not detect leukemia cells. But microscopy has a limit — it cannot reliably see a small number of residual cells. Measurable residual disease (MRD) testing closes that gap.
What MRD means
MRD refers to cancer cells that remain after treatment but are below the sensitivity of routine morphology. It is measured by multiparameter flow cytometry, quantitative PCR or next-generation sequencing, depending on the disease.
How it is used in leukemia
In AML and ALL, MRD after induction and consolidation predicts relapse risk. A persistent positive result may prompt a change in treatment or consideration of allogeneic transplant. In CML, BCR-ABL1 transcript monitoring guides tyrosine kinase inhibitor therapy.
How it is used in myeloma
MRD testing in the bone marrow complements protein response. It provides prognostic information and is increasingly used in clinical trials and selected practice.
What a result means — and does not mean
- A negative result means the disease is below the assay's detection limit, not necessarily cured.
- A positive result does not always require immediate treatment change.
- The assay, sample quality and timing all affect interpretation.
- Results should be compared using the same method over time.
Why the method matters
Flow cytometry, PCR and NGS have different sensitivities and different targets. A test that is appropriate for one leukemia may not be appropriate for another. The haematologist selects the assay based on the disease and the clinical question.
The bottom line
MRD is a powerful addition to blood cancer monitoring, but it is one piece of evidence. Treatment decisions integrate MRD with morphology, genetics, clinical response and patient factors.
Frequently asked questions
Answers reviewed by Dr. Jitendra Prasad Yadav • MBBS, MD (Internal Medicine), FICN (Neurology), FCNV, FIHM • NMC 8029
AML can be cured in a proportion of patients, particularly younger adults who achieve remission and proceed to appropriate consolidation or transplant. Outcomes vary widely with genetic subtype, age and fitness, so the treating team discusses prognosis for the individual case rather than giving a single figure.
Induction is the first phase of treatment, aiming to clear leukemia cells from the marrow and restore normal blood production. It usually requires hospital admission and close support with transfusion, infection prevention and monitoring.
Yes, ALL is the most common childhood cancer, but it also occurs in adults. Adult ALL often requires more intensive support and has a higher risk of relapse, so transplant assessment is more frequently considered.
ALL treatment includes several phases designed to clear leukemia, prevent CNS relapse and eliminate residual disease. Maintenance therapy can continue for months to years, with regular monitoring.
More: All FAQs → · Ask Dr. Jitendra →
Related articles
Flow Cytometry Explained: Reading the Immune Phenotype
Flow cytometry is central to diagnosing leukemia, lymphoma and plasma cell disorders. Learn what it measures and how to interpret the report.
Molecular Testing in Blood Cancer: What the Results Mean
Cytogenetics, FISH, PCR and next-generation sequencing guide diagnosis, risk and treatment in blood cancers.
CAR-T Cell Therapy: What Patients Should Know
CAR-T therapy is a cellular treatment for selected blood cancers. Learn how it works, who may be eligible and what monitoring involves.
Medical Disclaimer
Content on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.
References & Review
Reviewed by Dr. Jitendra Prasad Yadav • Last reviewed: 2026-11-10
- International Classification of Headache Disorders, 3rd edition (ICHD-3).
- Harrison's Principles of Internal Medicine — Neurology sections.
- American Academy of Neurology guidelines for selected conditions (where applicable).
Content is educational and aligns with standard medical references; individual evaluation may vary. External links provide context and do not imply endorsement.